Canada markets close in 6 minutes

Ovid Therapeutics Inc (1OT.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
2.72000.0000 (0.00%)
As of 08:02AM CET. Market open.
Full screen
Previous Close2.7200
Open2.7200
Bid2.7800 x 0
Ask2.9400 x 0
Day's Range2.7200 - 2.7200
52 Week Range2.2130 - 3.6800
Volume0
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 03, 2024 - May 07, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    Ovid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock Buying

    Last week, Ovid Therapeutics Inc. ( NASDAQ:OVID ) insiders, who had purchased shares in the previous 12 months were...

  • GlobeNewswire

    Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

    Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September 2024OV888 (GV101) is progressing on-track in a Phase 1, double-blind, multiple-ascending dose trial; a higher dose cohort has been added and no serious adverse events have been observed Feedback from a pre-IND session with the FDA supports potential initiation of a Phase 2 study of O

  • GlobeNewswire

    Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

    NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a panel titled “Orphan Epilepsies” at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts. A live webcast of the TD Cowen panel discussion can b